Briefing on mercury and autism

There is no doubt that the heavy metal mercury (Hg) is one of the most toxic substances on earth. The role of mercury as a major possible cause of autism has come to light only in the last 18 months after it was realised that the amount of mercury preservative in many vaccines was well in excess of recommended safety standards (Rimland 2001).

The concern has been highest in the USA where use of mercury is more widespread and indeed where the number of vaccines received by children is higher at earlier ages and often multiple vaccines are applied in a single day. Concerns have been expressed by parents following the revelation that the 75 symptoms of mercury poisoning parallel those for autism (Redwood 2000).

Mercury is used as a preservative under the name thiomersal (also known as thimerosal) in vaccines such as those against Hepatitis B and DPT (diphtheria, pertussis and tetanus) but is not used in live, attenuated vaccines such as MMR although some claims suggest that there may be trace elements found even in these products. In the UK childhood vaccines which definitely contain mercury include DPT and the DT (diphtheria and tetanus) preschool booster.

Mercury poisoning is often mistaken for a psychiatric disorder, especially when mercury exposure is not suspected (Bernard et al 2000). Exposure can also occur through maternal consumption of contaminated fish, dental amalgams, its use in antibiotics and other medications, and the anti D vaccination given to mothers during pregnancy or just after childbirth, which reduces the risk of RhD alloimmunisation in Rhesus negative women who have given birth to a Rhesus positive infant. There are concerns that mercury may be one element in a multiple�assault on�the system,�which could trigger autism spectrum conditions. These are speculative at present.

The causes of autism are currently, for the most part, unknown. 90% of cases are idiopathic (of unknown cause). Present knowledge suggests that autism is a strongly, but not wholly, genetic condition (Lamb et al 2000). It is thought to be a multigenic (more than one gene) condition (Turner, Barnby and Bailey 2000). It is likely that environmental factors also play a part in autism. What these environmental factors are is unclear. For this reason a number of candidates have been suggested, including the MMR vaccine and, more recently, mercury. Whilst these might be plausible suggestions there is, as yet, no sound scientific evidence to link autism with mercury. However, Geier and Geier (2003) suggest that there is strong epidemiological evidence for a link between increasing mercury from thiomersal-containing vaccines and neurodevelopmental disorders and heart disease. They argue for the immediate and complete removal of thiomersal from all childhood vaccines.

The European Agency for the Evaluation of Medicinal Products (EMEA) in its position statement (EMEA 2000) stresses the conclusions of the evaluation by the Centers for Disease Control and Prevention (CDC) in the USA into whether there is any epidemiological association between thiomersal-containing vaccines and specific neurological disorders in children. The evaluation found the studies made thus far to be inconclusive and lacking in sound scientific information. Further studies were recommended.

Meanwhile steps were being taken to eliminate organo-mercurials used as preservatives in the finished vaccine products. The EMEA’s Committee for Proprietary Medicinal Products (CPMP) recommended a step-wise approach to the removal of organo-mercurials in July 1999 provided that the benefit/risk analysis remains unchanged. The USA’s CDC has recommended a similar approach. This means that existing stocks of organo-mercurial containing vaccines are being used up by manufacturers. The explanation given for this is that it takes some while to make several changes to the manufacturing process.

The CPMP recommends continuing to vaccinate with existing vaccines including those containing thiomersal as they continue to offer benefits over and above the risks, if any, of exposure to mercury from these products. It recommends also that as a precautionary measure for vaccinating infants and toddlers that it would be prudent to use vaccines without mercurial-containing preservatives. The available thiomersal-free vaccines are recommended for use in newborn children.

Politically it may be seen to be unwise to raise concerns about safety, even at a precautionary level, but then to continue to use those vaccines. There is some anecdotal evidence that parents who wish to choose thiomersal-free vaccines for their children are not able always to achieve this.

Although The National Autistic Society (NAS) is not a medical research charity it has supported parents’ rights to choice for their children. The use of thiomersal-free vaccines is recommended and moves are underway towards the elimination of organo-mercurials. The NAS supports this process and urges all speed be made towards ensuring that these products are not used within the immunisation programme. Where mercury-free vaccines are available they should be used across the board as a precautionary measure although there is no persuasive evidence at present linking mercury with autism. It would also seem sensible to ensure that the constituents of vaccines and medications should always be clear both to health professionals and consumers.

In August 2004 the NHS announced that a new combined vaccine for diphtheria, tetanus, pertussis, Hib and polio was to be introduced from September 2004. The new vaccine does not contain thiomersal, which its predecessor did. The introduction of this thiomersal-free vaccine, according to the NHS press release, dated 09/08/2004, “meets the internationally agreed aim of reducing the exposure of children to mercury if it can be avoided”.


Bernard S. et al (2000) Autism: a unique type of mercury poisoning. Internet document:�Now available to download at
(accessed 06/01/05)

European Agency for the Evaluation of Medicinal Products (2000) EMEA position statement: recent developments concerning thiomersal in vaccines. London: EMEA.

Geier M. R. and Geier D. A. (2003) Thimerosal in childhood vaccines, neurodevelopment disorders and heart disease in the United States. Journal of American Physicians and Surgeons, 8 (1), pp. 6-11.

Lamb, J. A. et al (2000) Autism: recent molecular genetic advances. Human Molecular Genetics, 9, pp. 861-868.

NHS press release 9 August 2004: Improvements to childhood immunisation programme (accessed 06/01/2005)

Redwood L. (2000) Mercury and autism: coincidence or cause and effect? Autism Aspergers Digest, July-August, pp. 4-7.
Available from the NAS Information Centre

Rimland B. (2001) Mercury detoxification report nearing completion. Autism Research Review International, 15 (1), p. 1.
Available from the NAS Information Centre

Turner, M., Barnby, G. and Bailey, A. (2000) Genetic clues to the biological basis of autism. Molecular Medicine Today, 6, pp. 238-244.

Further Reading

Andrews, N. et al (2004) Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics, 114 (3), pp. 584-591.

Davidson, P. W., Myers, G. J. and Weiss, B. (2004) Mercury exposure and child development outcomes. Pediatrics, 113 (4 Suppl), pp. 1023-1029.

Hviid, A. et al (2003) Association between thimerosal-containing vaccine and autism. Journal of the American Medical Association, 290 (13), pp.1763-1766.

Kirby, D. (2005) Evidence of harm: mercury in vaccines and the autism epidemic: a medical controversy. New York: St Martin’s Press.

Madsen, K. M. et al (2003) Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics, 112 (3), pp. 604-606.

Parker, S. K. et al (2004) Thimerosal-containing vaccines and autistic spetrum disorder: a critical review of published original data. Pediatrics, 114 (3), pp. 793-804.

Rimland, B. (2003) The deceitful Danish studies. Autism Research Review International, 17 (3), p.3.
Available from the NAS Information Centre

Singh, V. K. and Rivas, W. H. (2004) Detection of antinuclear and antilaminin antibodies in autistic children who received thimerosal-containing vaccines. Journal of Biomedical Science, 11 (5), pp. 607-610.

Verstraeten T. et al. (2003) Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics, 112 (5), pp.1039-1048.

Vojdani, A. et al (2003) Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. International Journal of Immunopathology and Pharmacology, 16 (3), pp.189-199.

Waly, M. (2004) Activation of methionine synthase by insulin-like growth factor -1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Molecular Psychiatry, 9 (4), pp.358-370.

Any item shown as available from the NAS Information Centre may be ordered at a cost of �3.00 per article/book chapter, subject to copyright restrictions. Please complete the�Photocopy Request form (see ‘Related resources’ at the bottom of this page), and post it with your payment to the NAS Information Centre, 393 City Road, London EC1V 1NG, or fax to +44(0)20 7833 9666.�

Contact details for the NAS Information Centre:

Tel: +44 (0)845 070 4004 or email:

The NAS Information Centre produces fact sheets on a wide variety of topics and can provide customised reference lists in response to individual requests. These lists are extracted from Autism Data, our database which contains over 17,000 books and articles from the autism field. This service is particularly useful for those wanting to research a specific subject thoroughly.

Leave a Comment »

Comments RSS 2.0
1. IrisJOHNSON - February 13, 2011

Every body understands that our life is very expensive, but different people need cash for different things and not every person earns big sums money. So to get good loan and college loan would be a right solution.

« PEW SEEKS “COMMON VOICE” TO CONSERVE WHALES FOR THE 21st CENTURY // ERMA Confirms Scant Benefits from GM Brassica Trial »

FireStats icon Powered by FireStats